The findings support Enthera's clinical development of Ebrasodebart, a monoclonal antibody that targets the IGFBP3/TMEM219 pathway for the treatment of IBD, including UC and Crohn's disease.

Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 ...

Regulating TMEM219 by blocking the interaction between the protein and its ligand, IGFBP3, restored the self-renewal capabilities in vitro in patient-derived organoids (PDOs). These results were ...

The findings support Enthera’s clinical development of Ebrasodebart, a monoclonal antibody that targets the IGFBP3/TMEM219 pathway for the treatment of IBD, including UC and Crohn’s disease. The ...

Previous studies conducted by the same group of researchers had highlighted the importance of the IGFBP3 / TMEM219 signaling in the context of diabetes, particularly on insulin-producing beta cells.

Researchers of the University of Barcelona and the August Pi y Sunyer Biomedical Research Institute (IDIBAPS) have shown that the IGFBP3 protein plays a relevant role in human lung development ...

About 50% of patients with small intestine neuroendocrine tumors (SI-NETs) have their prognosis negatively impacted by the development of mesenteric fibrosis, but the mechanisms behind these are ...

Ent001 is a monoclonal antibody targeting the IGFBP3/TMEM219 pathway, which plays a critical role in gut mucosal integrity and is dysregulated in patients with inflammatory bowel diseases (IBD ...

Western blot analysis also demonstrated that CDK12 promoted VEGFA expression by inhibiting IGFBP3, which involves the Akt signaling pathway. Then, CDK12 was found to promote PCa cell proliferation, ...

Ent001 is a monoclonal antibody (mAb) targeting the IGFBP3/TMEM219 pathway, which plays a critical role in both inflammatory bowel disease (IBD) and type 1 diabetes (T1D). Elevated levels of ...

Ent001 is a monoclonal antibody (mAb) targeting the IGFBP3/TMEM219 pathway, which plays a critical role in both inflammatory bowel disease (IBD) and type 1 diabetes (T1D). Elevated levels of IGFBP3 ...